Stryker (NYSE:SYK) issued an update on its fourth quarter 2018 earnings guidance on Thursday morning. The company provided EPS guidance of $2.13-2.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.13. Stryker also updated its FY 2018 guidance to $7.25-7.30 EPS.
Shares of SYK stock traded down $4.89 during mid-day trading on Friday, reaching $160.38. 3,169,861 shares of the company’s stock traded hands, compared to its average volume of 1,325,300. Stryker has a 12 month low of $146.80 and a 12 month high of $179.84. The stock has a market cap of $62.74 billion, a PE ratio of 24.71, a price-to-earnings-growth ratio of 2.35 and a beta of 0.59. The company has a current ratio of 1.83, a quick ratio of 1.15 and a debt-to-equity ratio of 0.63.
Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 25th. The medical technology company reported $1.69 EPS for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.01. Stryker had a net margin of 8.28% and a return on equity of 26.93%. The firm had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.26 billion. On average, sell-side analysts forecast that Stryker will post 7.25 earnings per share for the current fiscal year.
SYK has been the topic of a number of research reports. Needham & Company LLC restated a hold rating on shares of Stryker in a report on Tuesday, September 11th. Canaccord Genuity restated a buy rating and set a $185.00 target price on shares of Stryker in a report on Wednesday, July 25th. Royal Bank of Canada restated a buy rating and set a $184.00 target price on shares of Stryker in a report on Wednesday, July 25th. Zacks Investment Research cut shares of Stryker from a buy rating to a hold rating in a report on Wednesday, August 8th. Finally, BTIG Research restated a buy rating and set a $187.00 target price on shares of Stryker in a report on Wednesday, September 12th. Eight investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Stryker has an average rating of Buy and an average target price of $180.71.
In related news, VP Katherine Ann Owen sold 37,866 shares of the company’s stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total value of $6,317,563.44. Following the transaction, the vice president now owns 11,367 shares in the company, valued at approximately $1,896,470.28. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Glenn S. Boehnlein sold 750 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $178.17, for a total transaction of $133,627.50. Following the completion of the transaction, the chief financial officer now owns 2,785 shares in the company, valued at approximately $496,203.45. The disclosure for this sale can be found here. Insiders own 7.30% of the company’s stock.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Read More: What Are Treasury Bonds?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.